Want to see OABI full AI Analyst Report?
OABI Stock Chart & Stats
$1.97
-$0.01(-0.51%)
At close: 4:00 PM EDT
$1.97
-$0.01(-0.51%)
Day’s Range― - ―
52-Week Range$1.30 - $2.79
Previous CloseN/A
Volume186.59K
Average Volume (3M)561.73K
Market Cap
$287.05M
Enterprise Value$171.94
Total Cash (Recent Filing)$49.07M
Total Debt (Recent Filing)$19.67M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 06, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding144,972,580
10 Day Avg. Volume481,153
30 Day Avg. Volume561,725
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)0.79
Price to Sales (P/S)11.26
P/FCF Ratio-5.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside255.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$30.80M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Raised GuidanceA large YoY revenue surge and upward guidance materially improves near-term revenue visibility. Because the bump is tied to partner milestones and clinical progress, it signals durable commercial traction in discovery services and increases the probability of further milestone receipts over the next 2–6 months.
Large Contracted Milestone & Royalty BaseA multi‑billion dollar contracted milestone pool and widespread royalty rights create a long-dated earnings lever. As partner programs advance, these contracts can convert lump-sum events into meaningful future cash inflows and royalties, anchoring the company’s long-term revenue potential.
Low Financial LeverageVery low debt reduces balance-sheet risk common in biotechs and preserves financial flexibility to fund operations or pursue partnerships. This durable structural advantage lowers default risk and supports the ability to raise capital or absorb milestone timing variability without excessive interest burden.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow increases reliance on external funding and creates dilution or financing risk. Over a multi‑quarter horizon, continued burn pressures runway and may force tradeoffs in R&D investment, commercial scaling, or unfavorable financing terms if milestone timings slip.
Milestone-driven Revenue VariabilityHeavy dependence on milestone events produces lumpy, unpredictable revenue and cash receipts. This structural volatility complicates operating planning, budgeting, and capital allocation, increasing execution risk and making sustained margin improvement harder to achieve absent diversification toward recurring revenue.
Limited Near-term Royalty ContributionRoyalties are the durable, long‑term revenue stream for a discovery-platform business; their current paucity means margins and cash flow remain tied to episodic milestones. Commercialization timelines and program attrition imply royalties may take years, leaving structural margin expansion uncertain in the medium term.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.30 and its highest was $2.79 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $287.05M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Aug 06, 2026 which is today.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on May 07, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.104 by $0.044.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.12.
How many shares outstanding does OmniAb have?
OmniAb has 144,972,580 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.104. Following the earnings report the stock price went up 12.925%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OmniAb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (255.33% Upside)
$7.00 (255.33% Upside)
Hedge Fund Trend
Decreased
By 285.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
OmniAb
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive operational and commercial momentum: a large YoY revenue surge driven by partner milestones, multiple clinical advancements (including OmnidAb entrants and a Phase III progression), improved operating efficiencies, raised revenue guidance, healthy technology traction (xPloration and OmniUltra) and a solid near-term cash balance. Offsetting items include a $2.9M noncash impairment that increased GAAP expense guidance, continued reliance on lumpy milestone revenue rather than royalties, ongoing net losses, and projected year-end cash decline. Overall, the positive operational and revenue developments and guidance raise materially outweigh the lowlights, though risks from milestone variability and funding remain.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$7.00
▲(255.33% Upside)
Technical Analysis
Cartesian Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
5.86% Insiders
9.90% Mutual Funds
3.16% Other Institutional Investors
72.65% Public Companies and
Individual Investors